These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32110830)

  • 1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
    Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro study of the variable effects of proton pump inhibitors on voriconazole.
    Niece KL; Boyd NK; Akers KS
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5548-54. PubMed ID: 26124167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
    Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y
    Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
    Modak AS; Klyarytska I; Kriviy V; Tsapyak T; Rabotyagova Y
    J Breath Res; 2016 Dec; 10(4):046017. PubMed ID: 27991432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
    Klieber M; Oberacher H; Hofstaetter S; Beer B; Neururer M; Amann A; Alber H; Modak A
    J Pharmacol Exp Ther; 2015 Sep; 354(3):426-30. PubMed ID: 26159874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
    Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients.
    Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M
    J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.
    Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL
    Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
    Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective disposition of proton pump inhibitors.
    Andersson T; Weidolf L
    Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.